The Food and Drug Administration announced Tuesday the approval of a new Alzheimer’s drug from Eli Lilly, which has demonstrated moderately slow cognitive and memory decline in patients with the disease.

The drug, donanemab, marketed under the label Kisunla, is a once-monthly monoclonal antibody infusion. The drug works by removing the excessive build-up of amyloid plaques in the brain, which are proteins thought to be the cause of thinking issues associated with Alzheimer’s disease.